表紙
市場調查報告書

高膽固醇症:開發中產品分析

Hypercholesterolemia - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 192645
出版日期 內容資訊 英文 277 Pages
訂單完成後即時交付
價格
Back to Top
高膽固醇症:開發中產品分析 Hypercholesterolemia - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 277 Pages
簡介

高膽固醇症是由於血液中高濃度的膽固醇所造成的。特別容易引發心血管疾病。膽固醇沈積在動脈,造成血管狹窄,限制血液的流通。致病因素有糖尿病、腎臟疾病、肥胖等各種疾病。此外還有遺傳、特定藥物、久坐的生活方式、抽煙、酒精成癮、壓力、高脂肪食物等。常見的症狀有動脈閉塞、下肢疼痛、胸部疼痛、膽固醇沉積等。治療方法包含了改善生活方式、改善飲食、戒煙、投藥等。

本報告提供高膽固醇症的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

高膽固醇症概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11771IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H2 2019, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 7, 14, 9, 2, 16, 6 and 4 respectively. Similarly, the Universities portfolio in Phase 0, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypercholesterolemia - Overview
    • Hypercholesterolemia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hypercholesterolemia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hypercholesterolemia - Companies Involved in Therapeutics Development
    • 3SBio Inc
    • AbbVie Inc
    • AD Pharmaceuticals Co Ltd
    • AFFiRiS AG
    • Akcea Therapeutics Inc
    • Amryt Pharma Plc
    • Arrowhead Pharmaceuticals Inc
    • AstraZeneca Plc
    • Beijing Mabworks Biotech Co Ltd
    • BioLingus AG
    • CardioPharma Inc
    • Centeer BioTherapeutics Ltd Co
    • Chong Kun Dang Pharmaceutical Corp
    • Civi Biopharma Inc
    • Cumberland Pharmaceuticals Inc
    • CymaBay Therapeutics Inc
    • Daewoong Co Ltd
    • Delivra Corp
    • Dogma Therapeutics Inc
    • Draupnir Bio Aps
    • Esperion Therapeutics Inc
    • Gemphire Therapeutics Inc
    • Golden Biotechnology Corp
    • Hingez Therapeutics Inc
    • Innovent Biologics Inc
    • Jiangsu Hengrui Medicine Co Ltd
    • Kadmon Corp LLC
    • Kyorin Pharmaceutical Co Ltd
    • LIB Therapeutics LLC
    • Lipigon Pharmaceuticals AB
    • LipimetiX Development Inc
    • Luye Pharma Group Ltd
    • Madrigal Pharmaceuticals Inc
    • Medlab Clinical Ltd
    • Novo Nordisk AS
    • Nyrada Inc
    • OliPass Corporation
    • Pfizer Inc
    • Portola Pharmaceuticals Inc
    • Precision Biosciences Inc
    • Progenra Inc
    • Regeneron Pharmaceuticals Inc
    • RegenxBio Inc
    • Repair Biotechnologies Inc
    • Shanghai Junshi Bioscience Co Ltd
    • Shenzhen HighTide Biopharmaceutical Ltd
    • Shifa Biomedical Corp
    • The Medicines Company
    • Viking Therapeutics Inc
    • Zhejiang Hisun Pharmaceutical Co Ltd
    • Zhejiang Teruisi Pharmaceutical Inc
  • Hypercholesterolemia - Drug Profiles
  • Hypercholesterolemia - Dormant Projects
  • Hypercholesterolemia - Discontinued Products
  • Hypercholesterolemia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hypercholesterolemia, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Hypercholesterolemia - Pipeline by 3SBio Inc, H2 2019
  • Hypercholesterolemia - Pipeline by AbbVie Inc, H2 2019
  • Hypercholesterolemia - Pipeline by AD Pharmaceuticals Co Ltd, H2 2019
  • Hypercholesterolemia - Pipeline by AFFiRiS AG, H2 2019
  • Hypercholesterolemia - Pipeline by Akcea Therapeutics Inc, H2 2019
  • Hypercholesterolemia - Pipeline by Amryt Pharma Plc, H2 2019
  • Hypercholesterolemia - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2019
  • Hypercholesterolemia - Pipeline by AstraZeneca Plc, H2 2019
  • Hypercholesterolemia - Pipeline by Beijing Mabworks Biotech Co Ltd, H2 2019
  • Hypercholesterolemia - Pipeline by BioLingus AG, H2 2019
  • Hypercholesterolemia - Pipeline by CardioPharma Inc, H2 2019
  • Hypercholesterolemia - Pipeline by Centeer BioTherapeutics Ltd Co, H2 2019
  • Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
  • Hypercholesterolemia - Pipeline by Civi Biopharma Inc, H2 2019
  • Hypercholesterolemia - Pipeline by Cumberland Pharmaceuticals Inc, H2 2019
  • Hypercholesterolemia - Pipeline by CymaBay Therapeutics Inc, H2 2019
  • Hypercholesterolemia - Pipeline by Daewoong Co Ltd, H2 2019
  • Hypercholesterolemia - Pipeline by Delivra Corp, H2 2019
  • Hypercholesterolemia - Pipeline by Dogma Therapeutics Inc, H2 2019
  • Hypercholesterolemia - Dormant Projects, H2 2019
  • Hypercholesterolemia - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Hypercholesterolemia, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top